Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy

World Journal of Urology

Volumn 26, Issue 5, 2008, Pages 447-456

  Williams, Scott G ^a   Zietman, Anthony L ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brachytherapy; Prostate cancer; Radiotherapy

Indexed keywords

BRACHYTHERAPY; HUMAN; MALE; PROSTATE TUMOR; RADIOTHERAPY; REVIEW; RISK FACTOR;

BRACHYTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS;

EID: 53549121408     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0305-9     Document Type: Review

References (98)

1. Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, Lebesque JV (2006) Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomised phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990-1996
2. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097-1105
3. Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294(10):1233-1239
4. Albertsen PC, Hanley JA, Gleason DF et al (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280(11):975-980
5. Shipley WU, Thames HD, Sandler HM et al (1999) Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281(17):1598-1604
6. Williams SG, Duchesne GM, Gogna NK et al (2006) An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. Int J Radiat Oncol Biol Phys 65(2):351-357
7. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969-974
8. Albertsen PC, Hanley JA, Barrows GH et al (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97(17):1248-1253
9. Chism DB, Hanlon AL, Troncoso P et al (2003) The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 56(5):1241-1247
10. Bahnson RR, Hanks GE, Huben RP et al (2000) NCCN practice guidelines for prostate cancer. Oncology (Williston Park) 14(11A):111-119
11. Yu HH, Song DY, Tsai YY et al (2007) Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology 70(1):111-116
12. Beard CJ, Chen MH, Cote K et al (2004) Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 58(1):19-24
13. Harnden P, Shelley MD, Clements H et al (2007) The prognostic significance of perineural invasion in prostatic cancer biopsies: A systematic review. Cancer 109(1):13-24
14. Williams SG, Buyyounouski MK, Pickles T et al (2008) Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. Int J Radiat Oncol Biol Phys 70(4):1169-1175
15. Weight CJ, Ciezki JP, Reddy CA et al (2006) Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 65(2):347-350
16. Stamey TA, Johnstone IM, McNeal JE et al (2002) Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml. correlate poorly with post-radical prostatectomy cancer morphology: Prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 167(1):103-111
17. Roehrborn CG, Boyle P, Gould AL et al (1999) Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53(3):581-589
18. Walz J, Gallina A, Perrotte P et al (2007) Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 100(6):1254-1258
19. Krahn MD, Bremner KE, Asaria J et al (2002) The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 60(2):258-263
20. Beyer DC, McKeough T, Thomas T (2005) Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61(5):1299-1305
21. Tward JD, Lee CM, Pappas LM et al (2006) Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: Impact of age at diagnosis. Cancer 107(10):2392-2400
22. Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52(1):6-13
23. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021-1031
24. King CR, Fowler JF (2001) A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51(1):213-214
25. Williams SG, Taylor JM, Liu N et al (2007) Use of individual fraction size data from 3,756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68(1):24-33
26. Lukka H, Hayter C, Julian JA et al (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23(25):6132-6138
27. Yeoh EE, Fraser RJ, McGowan RE et al (2003) Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 55(4):943-955
28. Miles EF, Lee WR (2008) Hypofractionation for prostate cancer: A critical review. Semin Radiat Oncol 18(1):41-47
29. Partin AW, Mangold LA, Lamm DM et al (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58(6):843-848
30. Sohayda C, Kupelian PA, Levin HS et al (2000) Extent of extracapsular extension in localized prostate cancer. Urology 55(3):382-386
31. Teh BS, Bastasch MD, Mai WY et al (2003) Predictors of extracapsular extension and its radial distance in prostate cancer: Implications for prostate IMRT, brachytherapy, and surgery. Cancer J 9(6):454-460
32. Skala M, Berry M, Duchesne G et al (2004) Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer. Australas Radiol 48(4):493-501
33. Boehmer D, Maingon P, Poortmans P et al (2006) Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 79(3):259-269
34. Zeliadt SB, Potosky AL, Penson DF et al (2006) Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 66(2):395-402
35. Keating NL, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448-4456
36. Trofimov A, Nguyen PL, Coen JJ et al (2007) Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: A treatment planning comparison. Int J Radiat Oncol Biol Phys 69(2):444-453
37. Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475-487
38. Cheung R, Tucker SL, Lee AK et al (2005) Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(4):993-1002
39. Hurwitz MD, Schnieder L, Manola J et al (2002) Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: A retrospective analysis. Int J Radiat Oncol Biol Phys 53(5):1106-1110
40. Zelefsky MJ, Fuks Z, Hunt M et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166(3):876-881
41. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67-74
42. Roach M, Lu J, Pilepich MV et al (2000) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47(3):609-615
43. Zelefsky MJ, Chan H, Hunt M et al (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176(4 Pt 1):1415-1419
44. Vora SA, Wong WW, Schild SE et al (2007) Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68(4):1053-1058
45. Turner SL, Adams K, Bull CA et al (1999) Sexual dysfunction after radical radiation therapy for prostate cancer: A prospective evaluation. Urology 54(1):124-129
46. Zelefsky MJ, Cowen D, Fuks Z et al (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85(11):2460-2468
47. Robinson JW, Moritz S, Fung T (2002) Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 54(4):1063-1068
48. Incrocci L, Koper PC, Hop WC et al (2001) Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: A randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 51(5):1190-1195
49. Incrocci L, Slob AK, Hop WC (2007) Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: An open-label extension of a blinded trial. Urology 70(6):1190-1193
50. Moseley DJ, White EA, Wiltshire KL et al (2007) Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 67(3):942-953
51. Scarbrough TJ, Golden NM, Ting JY et al (2006) Comparison of ultrasound and implanted seed marker prostate localization methods: Implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 65(2):378-387
52. Crook JM, Raymond Y, Salhani D et al (1995) Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 37(1):35-42
53. Kupelian P, Willoughby T, Mahadevan A et al (2007) Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 67(4):1088-1098
54. Cooperberg MR, Lubeck DP, Meng MV et al (2004) The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22(11):2141-2149
55. Nag S, Beyer D, Friedland J et al (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44(4):789-799
56. Pickett B, Kurhanewicz J, Coakley F et al (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60(4):1047-1055
57. Williams SG, Millar JL, Duchesne GM et al (2004) Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. Radiother Oncol 73(1):33-38
58. Ash D, Bottomley D, Al-Qaisieh B et al (2007) A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol 84(2):135-139
59. Merrick GS, Butler WM, Wallner KE et al (2003) Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 55(4):979-985
60. Lee WR, Hall MC, McQuellon RP et al (2001) A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 51(3):614-623
61. Crook J, McLean M, Catton C et al (2002) Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52(2):453-460
62. Gutman S, Merrick GS, Butler WM et al (2006) Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int 97(1):62-68
63. Martens C, Pond G, Webster D et al (2006) Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 5(1):9-13
64. Kollmeier MA, Stock RG, Cesaretti J et al (2005) Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 173(3):808-812
65. Merrick GS, Butler WM, Wallner KE et al (2004) Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 58(1):81-88
66. Macdonald AG, Keyes M, Kruk A et al (2005) Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 63(1):155-163
67. Merrick GS, Butler WM, Galbreath RW et al (2002) Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52(4):893-902
68. Mueller A, Wallner K, Merrick G et al (2004) Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys 59(4):1047-1052
69. Nag S, Ciezki JP, Cormack R et al (2001) Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 51(5):1422-1430
70. Zelefsky MJ, Yamada Y, Marion C et al (2003) Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 55(4):956-963
71. DiBiase SJ, Hosseinzadeh K, Gullapalli RP et al (2002) Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 52(2):429-438
72. Astrom L, Pedersen D, Mercke C et al (2005) Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 74(2):157-161 (Epub 2004 Nov 25)
73. Deger S, Boehmer D, Turk I et al (2002) High dose rate brachytherapy of localized prostate cancer. Eur Urol 41(4):420-426
74. Demanes DJ, Rodriguez RR, Altieri GA (2000) High dose rate prostate brachytherapy: The California endocurietherapy (CET) method. Radiother Oncol 57(3):289-296
75. Duchesne GM, Das R, Toye W et al (2002) Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: Influence of V150 and V200 parameters. Australas Radiol 46(4):384-389
76. Galalae RM, Martinez A, Mate T et al (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58(4):1048-1055
77. Martinez AA, Gustafson G, Gonzalez J et al (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53(2):316-327
78. Mate TP, Gottesman JE, Hatton J et al (1998) High dose-rate afterloading 192 Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 41(3):525-533
79. Duchesne GM, Peters LJ (1999) What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44(4):747-748
80. Galalae RM, Kovacs G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52(1):81-90
81. Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61(5):1306-1316
82. Grills IS, Martinez AA, Hollander M et al (2004) High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171(3):1098-1104
83. Mark R, Anderson P, Nair M (2007) Interstitial high-dose-rate (HDR) brachytherapy + IMRT vs. HDR monotherapy for early stage prostate cancer. Brachytherapy 6(2):93
84. Yoshioka Y, Nose T, Yoshida K et al (2003) High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56(1):213-220
85. Demanes D, Gilhezan M, Schour L et al (2007) High dose rate brachytherapy (HDR-BT) as monotherapy for favorable prostate cancer: excellent 5-year control rates and low toxicity. Int J Radiat Oncol Biol Phys 69(3S1):S83
86. Duchesne GM, Williams SG, Das R et al (2007) Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiother Oncol 84(2):128-134
87. Pellizzon AC, Salvajoli JV, Maia MA et al (2004) Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol 171(3):1105-1108
88. Martinez A, Gonzalez J, Spencer W et al (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169(3):974-979 (Discussion 979-980)
89. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN et al (2006) Do prostate cancer patients want to choose their own radiation treatment? Int J Radiat Oncol Biol Phys 66(4):1105-1111
90. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN et al (2006) Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol 24(28):4581-4586
91. Singh R, O'Brien TS (2004) Comorbidity assessment in localized prostate cancer: A review of currently available techniques. Eur Urol 46(1):28-41 discussion 41
92. Post PN, Hansen BE, Kil PJ et al (2001) The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: A population-based study. BJU Int 87(9):821-826
93. Konski A, Speier W, Hanlon A et al (2007) Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 25(24):3603-3608
94. Zietman AL (2007) The Titanic and the Iceberg: Prostate proton therapy and health care economics. J Clin Oncol 25(24):3565-3566
95. Brenner DJ, Curtis RE, Hall EJ et al (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88(2):398-406
96. Hall EJ, Wuu CS (2003) Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56(1):83-88
97. Hall EJ (2006) Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65(1):1-7
98. Pickles T, Phillips N (2002) The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol 65(3):145-151